Sally Bridget Lawlor Buys 10,244 Shares of Quoin Pharmaceuticals (NASDAQ:QNRX) Stock

Quoin Pharmaceuticals, Ltd. Sponsored ADR (NASDAQ:QNRX) CFO Sally Bridget Lawlor acquired 10,244 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The shares were acquired at an average cost of $4.88 per share, with a total value of $49,990.72. Following the completion of the transaction, the chief financial officer directly owned 10,684 shares in the company, valued at approximately $52,137.92. The trade was a 2,328.18% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Quoin Pharmaceuticals Stock Up 3.5%

NASDAQ:QNRX opened at $6.74 on Thursday. Quoin Pharmaceuticals, Ltd. Sponsored ADR has a 52 week low of $3.25 and a 52 week high of $41.80. The stock’s fifty day moving average is $4.83 and its two-hundred day moving average is $5.88. The stock has a market capitalization of $13.53 million, a price-to-earnings ratio of -0.27 and a beta of 1.50.

Quoin Pharmaceuticals (NASDAQ:QNRX) last announced its quarterly earnings data on Friday, August 14th. The company reported ($1.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.29). On average, sell-side analysts expect that Quoin Pharmaceuticals, Ltd. Sponsored ADR will post -7.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Quoin Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in QNRX. Simplify Asset Management Inc. acquired a new stake in shares of Quoin Pharmaceuticals in the fourth quarter valued at about $252,000. SummitTX Capital L.P. grew its position in Quoin Pharmaceuticals by 54.8% during the first quarter. SummitTX Capital L.P. now owns 100,300 shares of the company’s stock worth $662,000 after buying an additional 35,505 shares during the period. ADAR1 Capital Management LLC acquired a new position in Quoin Pharmaceuticals during the fourth quarter worth about $840,000. Boothbay Fund Management LLC purchased a new position in Quoin Pharmaceuticals in the fourth quarter valued at about $863,000. Finally, Millennium Management LLC purchased a new position in Quoin Pharmaceuticals in the fourth quarter valued at about $1,080,000. Institutional investors and hedge funds own 8.63% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on QNRX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Quoin Pharmaceuticals in a research report on Monday, July 20th. ThinkEquity started coverage on Quoin Pharmaceuticals in a research report on Monday, June 15th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold”.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc The company was founded in 2018 and is based in Ashburn, Virginia.